Patents by Inventor Michael Eisenhut

Michael Eisenhut has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20260007785
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: September 11, 2025
    Publication date: January 8, 2026
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20260007784
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: September 11, 2025
    Publication date: January 8, 2026
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20240382631
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: April 5, 2024
    Publication date: November 21, 2024
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20240350680
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: February 13, 2024
    Publication date: October 24, 2024
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer
    Patent number: 12054458
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers and imaging agents for various disease states of prostate cancer.
    Type: Grant
    Filed: March 17, 2023
    Date of Patent: August 6, 2024
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
    Inventors: Jens Cardinale, Martin Schaefer, Klaus Kopka, Matthias Eder, Ulrike Bauder-Wuest, Michael Eisenhut, Martina Benesova, Uwe Haberkorn, Frederik L. Giesel
  • Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer
    Patent number: 11951190
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: January 7, 2021
    Date of Patent: April 9, 2024
    Assignee: NOVARTIS AG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Michael Eisenhut, Walter Mier, Martina Benesova
  • Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer
    Patent number: 11931430
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: March 19, 2024
    Assignee: NOVARTIS AG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Michael Eisenhut, Walter Mier, Martina Benesova
  • 18F - TAGGED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND THEIR USE AS IMAGING AGENTS FOR PROSTATE CANCER
    Publication number: 20230295092
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers and imaging agents for various disease states of prostate cancer.
    Type: Application
    Filed: March 17, 2023
    Publication date: September 21, 2023
    Inventors: Jens Cardinale, Martin Schaefer, Klaus Kopka, Matthias Eder, Ulrike Bauder-Wuest, Michael Eisenhut, Martina Benesova, Uwe Haberkorn, Frederik L. Giesel
  • PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS WITH IMPROVED TISSUE SPECIFICITY
    Publication number: 20220118121
    Abstract: The present invention relates to a compound of formula (1), and to a complex comprising said compound and a radionuclide, and to the respective pharmaceutical composition, the compound having the following structure or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is H or —CH3, preferably H, wherein R2, R3 and R4 are independently of each other, selected from the group consisting of —CO2H, —SO2H, —SO3H, —OSO3H, —PO2H, —PO3H and —OPO3H2, Q1 is selected from the group consisting of alkylaryl, arylalkyl, aryl, alkylheteroaryl, heteroarylalkyl and heteroaryl, Q2 is selected from the group consisting of aryl, alkylaryl, arylalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl and alkylheteroaryl, A is a chelator residue derived from a chelator selected from the group consisting of 1,4,7,10-tetraazacyclododecane-N,N?,N?,N??-tetraacetic acid (=DOTA), N,N?-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N?-diacetic acid, 1,4,7-triazacyclononane-1,4,7-triacetic acid (=NOTA),
    Type: Application
    Filed: February 14, 2020
    Publication date: April 21, 2022
    Inventors: Matthias Eder, Ann-Christin Baranski, Michael Eisenhut, Uwe Haberkorn
  • USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20210283279
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: January 7, 2021
    Publication date: September 16, 2021
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer
    Patent number: 11045564
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: June 29, 2021
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Michael Eisenhut, Walter Mier, Martina Benesova
  • LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20210177996
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: December 3, 2020
    Publication date: June 17, 2021
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • 18F - TAGGED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND THEIR USE AS IMAGING AGENTS FOR PROSTATE CANCER
    Publication number: 20210053922
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers and imaging agents for various disease states of prostate cancer.
    Type: Application
    Filed: October 23, 2020
    Publication date: February 25, 2021
    Inventors: Jens CARDINALE, Martin SCHAEFER, Klaus KOPKA, Matthias EDER, Ulrike BAUDER-WUEST, Michael EISENHUT, Martina BENESOVA, Uwe HABERKORN, Frederik L. GIESEL
  • 18F—tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer
    Patent number: 10815200
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers and imaging agents for various disease states of prostate cancer.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: October 27, 2020
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
    Inventors: Jens Cardinale, Martin Schaefer, Klaus Kopka, Matthias Eder, Ulrike Bauder-Wuest, Michael Eisenhut, Martina Benesova, Uwe Haberkorn, Frederik L. Giesel
  • LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20190374660
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: August 26, 2019
    Publication date: December 12, 2019
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Uwe HABERKORN, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
    Patent number: 10471160
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: November 12, 2019
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Uwe Haberkorn, Michael Eisenhut, Walter Mier, Martina Benesova, Hans-Christian Kliem, Clemens Kratochwil
  • LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20190336622
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: July 12, 2019
    Publication date: November 7, 2019
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Uwe HABERKORN, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
    Patent number: 10398791
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: September 3, 2019
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Uwe Haberkorn, Michael Eisenhut, Walter Mier, Martina Benesova
  • LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20190060491
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: August 28, 2018
    Publication date: February 28, 2019
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Uwe HABERKORN, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20190008988
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: July 18, 2018
    Publication date: January 10, 2019
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Uwe HABERKORN, Michael EISENHUT, Walter MIER, Martina BENESOVA, Hans-Christian KLIEM, Clemens KRATOCHWIL